Novel Antibody Therapy Market, 2022-2035: Distribution by Type of Novel Antibody (Immunocytokines, Immunotoxins and Radioisotope Immunoconjugates), Target Indication (Acute Myeloid Leukemia, Bladder Cancer, Diffuse Large B-cell Lymphoma, Graft-versus-host disease, Melanoma Prostate Cancer and Soft-tissue Sarcoma), Type of Therapy (Combination Therapy and Monotherapy), Route of Administration (Intratumoral, Intravenous and Intravesical), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035
The novel antibody therapy market is expected to reach USD 2.4 billion in 2023 anticipated to grow at a CAGR of 36% during the forecast period 2022-2035.
Cancer persists as a prominent cause of worldwide mortality, and projections indicate a considerable increase in new cases by 2040. While conventional treatments such as chemotherapy and surgery have been pivotal, their limitations in advanced stages have prompted a shift toward exploring more targeted solutions. Emerging as a promising avenue are novel antibody therapies, specifically designed to selectively target and eliminate tumor cells. These therapies are available in diverse formats, bolstering their efficacy and precision in targeting affected cells, thereby exhibiting significant potential in multiple clinical trials as anti-cancer agents.
Six innovative antibody therapies—namely Adcetris®, Elzonris®, Lumoxiti®, Pluvicto™, Vicineum™, and Zevalin—have received approval for various oncological disorders. Additionally, more than 130 therapies are currently under evaluation at different stages. The realm of research in this field is expansive, involving over 50 companies and research institutions. Optimism surrounds the expectation of numerous promising treatments becoming accessible within the coming decade. The market for novel antibody therapies is characterized by substantial innovation, evident in the filing or granting of over 4,500 patents in recent times.
The advancement in this sector is propelled by collaborations between industry and academic stakeholders. Major pharmaceutical companies, along with emerging entities, contribute to further expanding the therapy pipeline. The ongoing positive clinical research and this momentum signify an anticipated steady growth in the novel antibody therapy market in the foreseeable future.
Report Coverage
Cancer persists as a prominent cause of worldwide mortality, and projections indicate a considerable increase in new cases by 2040. While conventional treatments such as chemotherapy and surgery have been pivotal, their limitations in advanced stages have prompted a shift toward exploring more targeted solutions. Emerging as a promising avenue are novel antibody therapies, specifically designed to selectively target and eliminate tumor cells. These therapies are available in diverse formats, bolstering their efficacy and precision in targeting affected cells, thereby exhibiting significant potential in multiple clinical trials as anti-cancer agents.
Six innovative antibody therapies—namely Adcetris®, Elzonris®, Lumoxiti®, Pluvicto™, Vicineum™, and Zevalin—have received approval for various oncological disorders. Additionally, more than 130 therapies are currently under evaluation at different stages. The realm of research in this field is expansive, involving over 50 companies and research institutions. Optimism surrounds the expectation of numerous promising treatments becoming accessible within the coming decade. The market for novel antibody therapies is characterized by substantial innovation, evident in the filing or granting of over 4,500 patents in recent times.
The advancement in this sector is propelled by collaborations between industry and academic stakeholders. Major pharmaceutical companies, along with emerging entities, contribute to further expanding the therapy pipeline. The ongoing positive clinical research and this momentum signify an anticipated steady growth in the novel antibody therapy market in the foreseeable future.
Report Coverage
- An executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the novel antibody therapies market in the mid to long term.
- A general overview of novel antibody therapies including information on the different types of novel antibody therapies. In addition, the chapter presents details on the novel antibody therapies (Antibody-Directed Enzyme Prodrug Therapy, TCR like Antibodies, Radioisotope Immunoconjugates, Immunotoxins, Intracellular Antibody and Immunocytokines). It also features information on developmental approaches of novel antibody therapies, limitations, and future of novel antibody therapies.
- An overview of the current market landscape of novel antibody therapies, such as immunocytokines, immunotoxins and radioisotopes immunoconjugates. In addition, the chapter includes a detailed analysis of these antibody therapies based on several relevant parameters. Immunocytokines have been analyzed based on status of development, mechanism of action, type of cytokine, type of antigen / format, dosing frequency type of therapy, mode of administration, route of administration, type of therapy and target disease indication(s).
- Detailed profiles of key players engaged in the development of novel antibody therapies. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
- Information on more than 550 completed, ongoing and planned clinical studies of novel antibody therapies, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), type of drug, emerging focus areas and regional distribution of trials.
- A detailed review of more than 570 peer-reviewed, scientific articles related to research on novel antibody therapies, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular publisher and copyright holders.(in terms of number of articles published).
- An in-depth analysis of the patents that have been filed / granted for novel antibody therapies, between 2017- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.
- An analysis of the partnerships that have been established in this domain, covering instances of acquisition, clinical trial agreement, commercialization agreement, distribution agreement, manufacturing agreement, product development agreement, product development and commercialization agreement, research and development agreement, supply agreement and other relevant types of deals.
- An analysis of big pharma players engaged in the field of novel antibody therapies, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of novel antibody, status of development, number of target indication, number of partnerships, number of patents and years of experience.
- An insightful market forecast analysis, highlighting the future potential of the novel antibody therapies market till the year 2035. It includes future sales projections of novel antibody therapies that are either marketed or are likely to be marketed within the next few years. In order to provide a detailed future outlook, our projections have been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).
- Actinium Pharmaceuticals
- Molecular Templates
- Philogen
- Roche
- Seagen
- Sesen bio
- Telix Pharmaceuticals
- Y-mAbs Therapeutics
1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
3.2.1.1. Mechanism of Action of ADEPT
3.2.1.2. Advantages of ADEPT
3.2.1.3. Disadvantages of ADEPT
3.2.2. TCR like Antibodies
3.2.2.1. Mechanism of Action of TCR like Antibodies
3.2.2.2. Advantages of TCR like Antibodies
3.2.2.3. Disadvantages of TCR like Antibodies
3.2.3. Radioisotope Immunoconjugates
3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
3.2.3.2. Advantages of Radioisotope Immunoconjugates
3.2.3.3. Disadvantages of Radioisotope Immunoconjugates
3.2.4. Immunotoxins
3.2.4.1. Mechanism of Action of Immunotoxins
3.2.4.2. Advantages of Immunotoxins
3.2.4.3. Disadvantages of Immunotoxins
3.2.5. Intracellular Antibody
3.2.5.1. Mechanism of Action of Intracellular Antibody
3.2.5.2. Advantages of Intracellular Antibody
3.2.5.3. Disadvantages of Intracellular Antibody
3.2.6. Immunocytokines
3.2.6.1. Mechanism of Action of Immunocytokines
3.2.6.2. Advantages of Immunocytokines
3.2.6.3. Disadvantages of Immunocytokines
3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives
4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Mechanism of Action
4.2.3. Analysis by Type of Cytokine
4.2.4. Analysis by Status of Development and Type of Cytokine
4.2.5. Analysis by Type of Antigen / Format
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Mode of Administration
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication(s)
4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.3.1. Analysis by Status of Development
4.3.2. Analysis by Mechanism of Action
4.3.3. Analysis by Type of Toxin
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Mode of Administration
4.3.7. Analysis by Immunotoxin Target
4.3.8. Analysis by Special Drug Designation
4.3.9. Analysis by Route of Administration
4.3.10. Analysis by Target Disease Indication(s)
4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.4.1. Analysis by Status of Development
4.4.2. Analysis by Type of Radio Isotopes
4.4.3. Analysis by Status of Development and Type of Radio Isotopes
4.4.4. Analysis by Route of Administration
4.4.5. Analysis by Type of Therapy
4.4.6. Analysis by Dosing Frequency
4.4.7. Analysis by Mode of Administration
4.4.8. Analysis by Special Drug Designation
4.4.9. Analysis by Target Disease Indication(s)
4.5. Novel Antibody Therapies: Development Pipeline (Other Novel Antibody)
4.6. Novel Antibody Therapies: List of Developers
4.6.1. Analysis by Type of Player
4.6.2. Analysis by Company Size
4.6.3. Analysis by Year of Establishment
4.6.4. Analysis by Company Size and Region of Headquarters
4.6.5. Leading Players: Analysis by Number of Therapeutics
4.6.6. Analysis by Location of Headquarters (Region-wise)
4.6.7. Analysis by Location of Headquarters (Country-wise)
5. COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Molecular Templates
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Philogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Roche
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Seagen
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Sesen bio
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Telix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Y-mAbs Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Trial Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Disease Indication(s)
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Type of Treatment
6.2.13. Analysis by Type of Drug
6.2.14. Word Cloud Analysis: Emerging Focus Areas
6.2.15. Analysis by Top Indication(s) and Trial Phase
6.2.16. Analysis by Top Indication(s) and Leading Industry Players
6.2.17. Analysis by Trial Location
6.2.18. Analysis by Geography and Trial Status
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Analysis by Type of Article
7.2.4. Key Journals: Analysis by Number of Publications
7.2.5. Key Journals: Analysis by Impact Factor
7.2.6. Most Popular Publishers: Analysis by Number of Publications
7.2.7. Most Popular Copyright Holders: Analysis by Number of Publications
8. PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
8.2.1. Analysis by Patent Publication Year
8.2.2. Year-wise Trend of Granted Patents
8.2.3. Analysis by Type of Patent
8.2.4. Analysis by Granted Patents and Patent Applications
8.2.5. Analysis by Geography
8.2.6. Analysis by CPC Symbols
8.2.7. Analysis by Type of Applicant
8.2.8. Analysis by Patent Age
8.2.9. Word Cloud Analysis: Emerging Focus Areas
8.2.10. Leading Industry Players: Analysis by Number of Patents
8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
8.2.12. Leading Individual Assignees: Analysis by Number of Patents
8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
8.2.14. Patent Valuation: Analysis Methodology and Parameters
8.2.15. Patent Valuation: Analysis by Relative Valuation
9. PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Year and Type of Partnership
9.1.4. Most Popular Drug: Analysis by Number of Partnerships
9.1.5. Analysis by Types of Novel Antibodies
9.1.6. Analysis by Type of Partner
9.1.7. Analysis by Partner Company and Type of Partnership
9.1.8. Analysis by Popular Disease Indication(s)
9.1.9. Analysis by Popular Disease Indication and Type of Partnership
9.1.10. Regional Analysis of Partnerships
9.1.11. Intercontinental and Intracontinental Agreements
10. BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. List of Big Pharma Players Focused on Novel Antibody Therapies
10.3. Scoring Criteria for Key Parameters
10.3.1. Analysis by Supplier Strength
10.3.2. Analysis by Portfolio Strength
10.3.3. Analysis by Portfolio Diversity
10.3.4. Benchmarking: Spider Web Analysis
10.3.5. Benchmarking: Harvey Ball Analysis
10.3.6. Benchmarking: Wind Rose Chart
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.3.1. Adcetris (Seagen)
11.3.1.2. Sales Forecast
11.3.2. Elzonris (Menarini Group)
11.3.2.2. Sales Forecast
11.3.3. Pluvicto (Novartis)
11.3.3.2. Sales Forecast
11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035
11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035
11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035
11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035
11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035
11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.1.1. Target Patient Population
11.9.1.2. Sales Forecast
11.9.1.3. Net Present Value
11.9.1.4. Value Creation Analysis
11.9.2. Fibromun (Philogen)
11.9.2.1. Target Patient Population
11.9.2.2. Sales Forecast
11.9.2.3. Net Present Value
11.9.2.4. Value Creation Analysis
11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.3.1. Target Patient Population
11.9.3.2. Sales Forecast
11.9.3.3. Net Present Value
11.9.3.4. Value Creation Analysis
11.9.4. Nidlegy (Philogen)
11.9.4.1. Target Patient Population
11.9.4.2. Sales Forecast
11.9.4.3. Net Present Value
11.9.4.4. Value Creation Analysis
11.9.5. T-Guard (Xenikos)
11.9.5.1. Target Patient Population
11.9.5.2. Sales Forecast
11.9.5.3. Net Present Value
11.9.5.4. Value Creation Analysis
11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.6.1. Target Patient Population
11.9.6.2. Sales Forecast
11.9.6.3. Net Present Value
11.9.6.4. Value Creation Analysis
11.9.7. Vicinium (Sesen Bio)
11.9.7.1. Target Patient Population
11.9.7.2. Sales Forecast
11.9.7.3. Net Present Value
11.9.7.4. Value Creation Analysis
12. APPENDIX 1: TABULATED DATA
13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
3.2.1.1. Mechanism of Action of ADEPT
3.2.1.2. Advantages of ADEPT
3.2.1.3. Disadvantages of ADEPT
3.2.2. TCR like Antibodies
3.2.2.1. Mechanism of Action of TCR like Antibodies
3.2.2.2. Advantages of TCR like Antibodies
3.2.2.3. Disadvantages of TCR like Antibodies
3.2.3. Radioisotope Immunoconjugates
3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
3.2.3.2. Advantages of Radioisotope Immunoconjugates
3.2.3.3. Disadvantages of Radioisotope Immunoconjugates
3.2.4. Immunotoxins
3.2.4.1. Mechanism of Action of Immunotoxins
3.2.4.2. Advantages of Immunotoxins
3.2.4.3. Disadvantages of Immunotoxins
3.2.5. Intracellular Antibody
3.2.5.1. Mechanism of Action of Intracellular Antibody
3.2.5.2. Advantages of Intracellular Antibody
3.2.5.3. Disadvantages of Intracellular Antibody
3.2.6. Immunocytokines
3.2.6.1. Mechanism of Action of Immunocytokines
3.2.6.2. Advantages of Immunocytokines
3.2.6.3. Disadvantages of Immunocytokines
3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives
4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Mechanism of Action
4.2.3. Analysis by Type of Cytokine
4.2.4. Analysis by Status of Development and Type of Cytokine
4.2.5. Analysis by Type of Antigen / Format
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Mode of Administration
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication(s)
4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.3.1. Analysis by Status of Development
4.3.2. Analysis by Mechanism of Action
4.3.3. Analysis by Type of Toxin
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Mode of Administration
4.3.7. Analysis by Immunotoxin Target
4.3.8. Analysis by Special Drug Designation
4.3.9. Analysis by Route of Administration
4.3.10. Analysis by Target Disease Indication(s)
4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.4.1. Analysis by Status of Development
4.4.2. Analysis by Type of Radio Isotopes
4.4.3. Analysis by Status of Development and Type of Radio Isotopes
4.4.4. Analysis by Route of Administration
4.4.5. Analysis by Type of Therapy
4.4.6. Analysis by Dosing Frequency
4.4.7. Analysis by Mode of Administration
4.4.8. Analysis by Special Drug Designation
4.4.9. Analysis by Target Disease Indication(s)
4.5. Novel Antibody Therapies: Development Pipeline (Other Novel Antibody)
4.6. Novel Antibody Therapies: List of Developers
4.6.1. Analysis by Type of Player
4.6.2. Analysis by Company Size
4.6.3. Analysis by Year of Establishment
4.6.4. Analysis by Company Size and Region of Headquarters
4.6.5. Leading Players: Analysis by Number of Therapeutics
4.6.6. Analysis by Location of Headquarters (Region-wise)
4.6.7. Analysis by Location of Headquarters (Country-wise)
5. COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Molecular Templates
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Philogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Roche
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Seagen
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Sesen bio
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Telix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Y-mAbs Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Trial Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Disease Indication(s)
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Type of Treatment
6.2.13. Analysis by Type of Drug
6.2.14. Word Cloud Analysis: Emerging Focus Areas
6.2.15. Analysis by Top Indication(s) and Trial Phase
6.2.16. Analysis by Top Indication(s) and Leading Industry Players
6.2.17. Analysis by Trial Location
6.2.18. Analysis by Geography and Trial Status
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Analysis by Type of Article
7.2.4. Key Journals: Analysis by Number of Publications
7.2.5. Key Journals: Analysis by Impact Factor
7.2.6. Most Popular Publishers: Analysis by Number of Publications
7.2.7. Most Popular Copyright Holders: Analysis by Number of Publications
8. PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
8.2.1. Analysis by Patent Publication Year
8.2.2. Year-wise Trend of Granted Patents
8.2.3. Analysis by Type of Patent
8.2.4. Analysis by Granted Patents and Patent Applications
8.2.5. Analysis by Geography
8.2.6. Analysis by CPC Symbols
8.2.7. Analysis by Type of Applicant
8.2.8. Analysis by Patent Age
8.2.9. Word Cloud Analysis: Emerging Focus Areas
8.2.10. Leading Industry Players: Analysis by Number of Patents
8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
8.2.12. Leading Individual Assignees: Analysis by Number of Patents
8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
8.2.14. Patent Valuation: Analysis Methodology and Parameters
8.2.15. Patent Valuation: Analysis by Relative Valuation
9. PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Year and Type of Partnership
9.1.4. Most Popular Drug: Analysis by Number of Partnerships
9.1.5. Analysis by Types of Novel Antibodies
9.1.6. Analysis by Type of Partner
9.1.7. Analysis by Partner Company and Type of Partnership
9.1.8. Analysis by Popular Disease Indication(s)
9.1.9. Analysis by Popular Disease Indication and Type of Partnership
9.1.10. Regional Analysis of Partnerships
9.1.11. Intercontinental and Intracontinental Agreements
10. BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. List of Big Pharma Players Focused on Novel Antibody Therapies
10.3. Scoring Criteria for Key Parameters
10.3.1. Analysis by Supplier Strength
10.3.2. Analysis by Portfolio Strength
10.3.3. Analysis by Portfolio Diversity
10.3.4. Benchmarking: Spider Web Analysis
10.3.5. Benchmarking: Harvey Ball Analysis
10.3.6. Benchmarking: Wind Rose Chart
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.3.1. Adcetris (Seagen)
11.3.1.2. Sales Forecast
11.3.2. Elzonris (Menarini Group)
11.3.2.2. Sales Forecast
11.3.3. Pluvicto (Novartis)
11.3.3.2. Sales Forecast
11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035
11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035
11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035
11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035
11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035
11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.1.1. Target Patient Population
11.9.1.2. Sales Forecast
11.9.1.3. Net Present Value
11.9.1.4. Value Creation Analysis
11.9.2. Fibromun (Philogen)
11.9.2.1. Target Patient Population
11.9.2.2. Sales Forecast
11.9.2.3. Net Present Value
11.9.2.4. Value Creation Analysis
11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.3.1. Target Patient Population
11.9.3.2. Sales Forecast
11.9.3.3. Net Present Value
11.9.3.4. Value Creation Analysis
11.9.4. Nidlegy (Philogen)
11.9.4.1. Target Patient Population
11.9.4.2. Sales Forecast
11.9.4.3. Net Present Value
11.9.4.4. Value Creation Analysis
11.9.5. T-Guard (Xenikos)
11.9.5.1. Target Patient Population
11.9.5.2. Sales Forecast
11.9.5.3. Net Present Value
11.9.5.4. Value Creation Analysis
11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.6.1. Target Patient Population
11.9.6.2. Sales Forecast
11.9.6.3. Net Present Value
11.9.6.4. Value Creation Analysis
11.9.7. Vicinium (Sesen Bio)
11.9.7.1. Target Patient Population
11.9.7.2. Sales Forecast
11.9.7.3. Net Present Value
11.9.7.4. Value Creation Analysis
12. APPENDIX 1: TABULATED DATA
13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
